Literature DB >> 31288935

Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes.

Alan Zambeli-Ljepović1, Frances Wang1, Michaela A Dinan1, Terry Hyslop1, Michael T Stang1, Sanziana A Roman2, Julie A Sosa2, Randall P Scheri3.   

Abstract

BACKGROUND: Total thyroidectomy is more common than lobectomy for low-risk papillary thyroid cancer, despite equipoise in survival. Because postoperative morbidity increases with age, we aimed to investigate how the extent of thyroidectomy affects short-term outcomes among older patients.
METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients aged ≥66 years who were treated between 1996 and 2011 for papillary thyroid cancer with tumors ≤2 cm in diameter. We used multivariable logistic regression to evaluate the effect of extent of surgery on complications, emergency-department visits, and unplanned readmissions.
RESULTS: Among 3,341 selected patients, 77.3% were female, mean age was 72.9 years, and tumors averaged 0.8 cm in diameter. A total of 67.6% of patients underwent total thyroidectomy, and 32.4% underwent lobectomy. Total thyroidectomy was associated with complications (odds ratio = 1.99) and readmissions (odds ratio = 1.59; both P < 0.01). Complications were higher in female patients (odds ratio = 1.34), black patients (versus white patients, odds ratio = 1.65), and those with ≥2 comorbidities (vs 0, odds ratio = 1.43; all P < 0.01). Black patients and those with ≥2 comorbidities had more emergency-department visits (odds ratio = 1.50 and 1.92, respectively) and readmissions (odds ratio = 2.19 and 2.29, respectively; all P < 0.01).
CONCLUSION: Total thyroidectomy for older adults with low-risk papillary thyroid cancer may lead to potentially avoidable complications and readmissions, particularly for black and female patients. In many cases, lobectomy may be a safer and less costly alternative.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31288935      PMCID: PMC6802283          DOI: 10.1016/j.surg.2019.05.035

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

1.  Readmission rates and cost following colorectal surgery.

Authors:  Elizabeth C Wick; Andrew D Shore; Kenzo Hirose; Andrew M Ibrahim; Susan L Gearhart; Jonathan Efron; Jonathan P Weiner; Martin A Makary
Journal:  Dis Colon Rectum       Date:  2011-12       Impact factor: 4.585

2.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

3.  Risk scoring can predict readmission after endocrine surgery.

Authors:  James C Iannuzzi; Fergal J Fleming; Kristin N Kelly; Daniel T Ruan; John R Monson; Jacob Moalem
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

4.  Understanding readmissions following operations of the thyroid and parathyroid glands.

Authors:  Karole Collier; John Sataloff; Chris Wirtalla; Lindsay Kuo; Giorgos C Karakousis; Rachel R Kelz
Journal:  Am J Surg       Date:  2017-01-10       Impact factor: 2.565

5.  Thirty-day and 90-day hospital readmission after outpatient upper extremity hemodialysis access creation.

Authors:  Jeffrey J Siracuse; Nishant K Shah; Matthew R Peacock; Georges Tahhan; Jeffrey A Kalish; Denis Rybin; Mohammad H Eslami; Alik Farber
Journal:  J Vasc Surg       Date:  2017-02-20       Impact factor: 4.268

6.  Early versus late readmission after surgery among patients with employer-provided health insurance.

Authors:  Yuhree Kim; Faiz Gani; Donald J Lucas; Aslam Ejaz; Gaya Spolverato; Joseph K Canner; Eric B Schneider; Timothy M Pawlik
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

7.  Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.

Authors:  Mohamed Abdelgadir Adam; John Pura; Lin Gu; Michaela A Dinan; Douglas S Tyler; Shelby D Reed; Randall Scheri; Sanziana A Roman; Julie A Sosa
Journal:  Ann Surg       Date:  2014-10       Impact factor: 12.969

8.  Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons.

Authors:  Adam Hauch; Zaid Al-Qurayshi; Gregory Randolph; Emad Kandil
Journal:  Ann Surg Oncol       Date:  2014-06-19       Impact factor: 5.344

9.  Racial disparities in clinical and economic outcomes from thyroidectomy.

Authors:  Julie Ann Sosa; Pritesh J Mehta; Tracy S Wang; Heather L Yeo; Sanziana A Roman
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

10.  The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients.

Authors:  Carrie C Lubitz; Julie A Sosa
Journal:  Cancer       Date:  2016-08-12       Impact factor: 6.860

View more
  4 in total

1.  Long-Term Survival in Patients With Papillary Thyroid Cancer Who Did Not Undergo Prophylactic Central Lymph Node Dissection: A SEER-Based Study.

Authors:  Jun Long Song; Ling Rui Li; Zhi Liang Xu; Juan Juan Li; Sheng Rong Sun; Chuang Chen
Journal:  World J Oncol       Date:  2022-06-02

2.  Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance: A Systematic Review and Meta-analysis.

Authors:  Alexandra Koshkina; Rouhi Fazelzad; Iwao Sugitani; Akira Miyauchi; Lehana Thabane; David P Goldstein; Sangeet Ghai; Anna M Sawka
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-06-01       Impact factor: 6.223

Review 3.  Updates on the Management of Thyroid Cancer.

Authors:  Katherine A Araque; Sriram Gubbi; Joanna Klubo-Gwiezdzinska
Journal:  Horm Metab Res       Date:  2020-02-10       Impact factor: 2.936

4.  Clinical assessment of T2 papillary thyroid carcinoma: a retrospective study conducted at a single tertiary institution.

Authors:  Hyesung Kim; Kwangsoon Kim; Ja Seong Bae; Jeong Soo Kim
Journal:  Sci Rep       Date:  2022-08-08       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.